Bioequivalence Study of Favir 200 mg Film Tablet Kocak Under Fasting Conditions
Status:
Completed
Trial end date:
2020-06-13
Target enrollment:
Participant gender:
Summary
A single dose of Reference product containing 200 mg favipiravir and a single dose of Test
product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at
room temperature, in each period under fasting conditions with current pandemic precautions.
Phase:
Phase 1
Details
Lead Sponsor:
Kocak Farma
Collaborators:
Farmagen Ar-Ge Biyot. Ltd. Sti Novagenix Bioanalytical Drug R&D Center